X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON LTD ALKEM LABORATORIES/
BIOCON LTD
 
P/E (TTM) x - 39.5 - View Chart
P/BV x 6.1 5.3 117.0% View Chart
Dividend Yield % 0.7 1.4 50.1%  

Financials

 ALKEM LABORATORIES   BIOCON LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON LTD
Mar-16
ALKEM LABORATORIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,589496 320.6%   
Low Rs1,232397 310.7%   
Sales per share (Unadj.) Rs417.5174.3 239.5%  
Earnings per share (Unadj.) Rs56.344.8 125.6%  
Cash flow per share (Unadj.) Rs64.756.9 113.7%  
Dividends per share (Unadj.) Rs12.705.00 254.0%  
Dividend yield (eoy) %0.91.1 80.3%  
Book value per share (Unadj.) Rs292.9202.8 144.5%  
Shares outstanding (eoy) m119.57200.00 59.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.6 132.0%   
Avg P/E ratio x25.110.0 251.7%  
P/CF ratio (eoy) x21.87.8 278.1%  
Price / Book Value ratio x4.82.2 218.9%  
Dividend payout %22.611.2 202.2%   
Avg Mkt Cap Rs m168,65389,220 189.0%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m9,1716,363 144.1%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m49,91534,854 143.2%  
Other income Rs m1,645845 194.7%   
Total revenues Rs m51,56135,699 144.4%   
Gross profit Rs m8,4828,200 103.4%  
Depreciation Rs m1,0062,423 41.5%   
Interest Rs m671102 657.5%   
Profit before tax Rs m8,4516,520 129.6%   
Minority Interest Rs m-114-744 15.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m1,6062,569 62.5%   
Profit after tax Rs m6,7318,961 75.1%  
Gross profit margin %17.023.5 72.2%  
Effective tax rate %19.039.4 48.2%   
Net profit margin %13.525.7 52.5%  
BALANCE SHEET DATA
Current assets Rs m27,06239,932 67.8%   
Current liabilities Rs m15,32416,276 94.1%   
Net working cap to sales %23.567.9 34.6%  
Current ratio x1.82.5 72.0%  
Inventory Days Days6754 124.2%  
Debtors Days Days4186 47.9%  
Net fixed assets Rs m12,61039,101 32.2%   
Share capital Rs m2391,000 23.9%   
"Free" reserves Rs m34,49038,591 89.4%   
Net worth Rs m35,02740,556 86.4%   
Long term debt Rs m1,21220,724 5.8%   
Total assets Rs m54,38784,816 64.1%  
Interest coverage x13.664.9 21.0%   
Debt to equity ratio x00.5 6.8%  
Sales to assets ratio x0.90.4 223.3%   
Return on assets %13.610.7 127.4%  
Return on equity %19.222.1 87.0%  
Return on capital %24.919.0 131.0%  
Exports to sales %12.930.7 42.1%   
Imports to sales %3.120.4 15.1%   
Exports (fob) Rs m6,46110,717 60.3%   
Imports (cif) Rs m1,5407,105 21.7%   
Fx inflow Rs m6,56311,789 55.7%   
Fx outflow Rs m3,0128,393 35.9%   
Net fx Rs m3,5523,396 104.6%   
CASH FLOW
From Operations Rs m7,2595,264 137.9%  
From Investments Rs m1,864-9,540 -19.5%  
From Financial Activity Rs m-9,27310,867 -85.3%  
Net Cashflow Rs m-1506,591 -2.3%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 22, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SUVEN LIFE COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS